Financial reports

Read more:

Categories

Archive per year

Nanologica’s Interim Report Jan-Sep 2022

FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 401 (2,119) and for the nine-month period to TSEK 881 (12,238) The operating result for the quarter amounted to TSEK -9,610 (-11,718) and for the nine-month period to TSEK -37,599 (-26,581) Result after tax for the quarter amounted to TSEK -10,988 (-12,546) and for the nine-month period to TSEK -40,376 (-29,607) Earnings per share before and after dilution were SEK -0.39 (-0.45) for the

Read more »

Nanologica’s Interim Report Jan – Jun 2022

FINANCIAL SUMMARY Net sales for the quarter amounted to TSEK 210 (4,497) and for the half-year to TSEK 479 (10,119) The operating result for the quarter amounted to TSEK -12,397 (-8,094) and for the half-year to TSEK -27,989 (-14,862) Result after tax for the quarter amounted to TSEK -13,473 (-9,216) and for the half-year to TSEK -29,388 (-17,061) Earnings per share before and after dilution were SEK -0.48 (-0.33) for the quarter and SEK -1.04

Read more »

Nanologica’s Interim Report Jan-Mar 2022

PERIOD IN BRIEF FINANCIAL SUMMARY Net sales for the first quarter amounted to TSEK 270 (5,622) The operating result amounted to TSEK -15,592 (-6,768) Result after tax amounted to TSEK -15,915 (-7,845) Earnings per share before and after dilution were SEK -0.57 (-0.28) Cash and cash equivalents amounted to TSEK 3,969 (57,069) as per March 31, 2022 SIGNIFICANT EVENTS IN THE FIRST QUARTER In January, a credit facility of up to MSEK 50 was signed

Read more »

Nanologica’s Year-End Report 2021

FINANCIAL SUMMARY Net sales for the fourth quarter amounted to TSEK 676 (6,071) and for the full year to TSEK 12,914 (16,135) The operating result for the fourth quarter amounted to TSEK -14,108 (-3,648) and for the full year to TSEK -40,689 (-19,571) Result after tax for the fourth quarter amounted to TSEK -15,222 (-5,427) and for the full year to TSEK -44,829 (-22,199) Earnings per share before and after dilution were SEK -0,54 (-0,20)

Read more »

Nanologica Interim Report Jan – Sep 2021

FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 2,119 (2,089) and for the nine-month period to TSEK 12,238 (10,064) The operating result for the quarter amounted to TSEK -11,718 (-5,795) and for the nine-month period to TSEK -26,581 (-15,924) Result after tax for the quarter amounted to TSEK -12,546 (-5,899) and for the nine-month period to TSEK -29,607 (-16,772) Earnings per share before and after dilution were SEK -0.45 (-0.21) for the

Read more »